全文获取类型
收费全文 | 1405066篇 |
免费 | 118295篇 |
国内免费 | 6523篇 |
专业分类
耳鼻咽喉 | 17620篇 |
儿科学 | 44449篇 |
妇产科学 | 38009篇 |
基础医学 | 193411篇 |
口腔科学 | 38878篇 |
临床医学 | 125813篇 |
内科学 | 293974篇 |
皮肤病学 | 33673篇 |
神经病学 | 116520篇 |
特种医学 | 58291篇 |
外国民族医学 | 274篇 |
外科学 | 219481篇 |
综合类 | 31829篇 |
现状与发展 | 2篇 |
一般理论 | 438篇 |
预防医学 | 112492篇 |
眼科学 | 29288篇 |
药学 | 98642篇 |
5篇 | |
中国医学 | 2519篇 |
肿瘤学 | 74276篇 |
出版年
2018年 | 15435篇 |
2017年 | 11881篇 |
2016年 | 14128篇 |
2015年 | 16233篇 |
2014年 | 22017篇 |
2013年 | 32805篇 |
2012年 | 42176篇 |
2011年 | 44964篇 |
2010年 | 27171篇 |
2009年 | 25791篇 |
2008年 | 41404篇 |
2007年 | 44142篇 |
2006年 | 45417篇 |
2005年 | 43550篇 |
2004年 | 41278篇 |
2003年 | 39978篇 |
2002年 | 37791篇 |
2001年 | 67432篇 |
2000年 | 69778篇 |
1999年 | 57508篇 |
1998年 | 16941篇 |
1997年 | 15181篇 |
1996年 | 16158篇 |
1995年 | 16379篇 |
1994年 | 15210篇 |
1993年 | 14255篇 |
1992年 | 47217篇 |
1991年 | 45857篇 |
1990年 | 44048篇 |
1989年 | 41894篇 |
1988年 | 38827篇 |
1987年 | 38140篇 |
1986年 | 35930篇 |
1985年 | 34731篇 |
1984年 | 26447篇 |
1983年 | 22171篇 |
1982年 | 13930篇 |
1981年 | 12525篇 |
1980年 | 11803篇 |
1979年 | 23596篇 |
1978年 | 17133篇 |
1977年 | 14430篇 |
1976年 | 13227篇 |
1975年 | 13764篇 |
1974年 | 16140篇 |
1973年 | 15435篇 |
1972年 | 14188篇 |
1971年 | 13064篇 |
1970年 | 11902篇 |
1969年 | 11122篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Guerard W. Byrne Johannes M. Schirmer David N. Fass Sumeet S. Teotia Walter K. Kremers Hui Xu Bashoo Naziruddin Henry D. Tazelaar John S. Logan Christopher G. A. McGregor 《American journal of transplantation》2005,5(5):1011-1020
Microvascular thrombosis is a prominent feature in cardiac delayed xenograft rejection (DXR). We investigated the impact of warfarin or low-molecular-weight heparin (LMWH) anti-coagulation on xenograft function using a heterotopic pig-to-primate model. Donor hearts were from CD46 transgenic pigs and baboon immunosuppression included tacrolimus, sirolimus, anti-CD20 and TPC, an alpha-galactosyl-polyethylene glycol conjugate. Three groups of animals were studied. Group 1 (n = 9) was treated with warfarin, Group 2 (n = 13) with LMWH and Group 3, received no anti-coagulant drugs. The median duration of xenograft function was 20 days (range 3-62 days), 18 days (range 5-109 days) and 15 days (range 4-53 days) in Groups 1 to 3 respectively. Anti-coagulation achieved the targeted international normalized prothrombin ratio (INR) and anti-factor Xa levels consistent with effective in vivo therapy yet, no significant impact on median xenograft function was observed. At rejection, a similar histology of thrombosis and ischemia was apparent in each group and the levels of fibrin deposition and platelet thrombi in rejected tissue was the same. Anti-coagulation with warfarin or LMWH did not have a significant impact on the onset of DXR and microvascular thrombosis. However, a role for specific anti-coagulant strategies to achieve long-term xenograft function cannot be excluded. 相似文献
992.
993.
Trauma und Berufskrankheit - Als schwerste Komplikation der Gelenkendoprothetik bleibt die periprothetische Infektion eine Herausforderung—heutzutage nicht nur für den Chirurgen, sondern... 相似文献
994.
995.
U. Bolm-Audorff S. Brandenburg T. Brüning H. Dupuis R. Ellegast G. Elsner K. Franz H. Grasshoff V. Grosser L. Hanisch B. Hartmann E. Hartung K. G. Hering G. Heuchert M. Jäger J. Krämer Dr. A. Kranig E. Ludolph A. Luttmann A. Nienhaus W. Pieper K.-D. Pöhl T. Remé D. Riede G. Rompe K. Schäfer S. Schilling E. Schmitt F. Schröter A. Seidler M. Spallek M. Weber 《Trauma und Berufskrankheit》2005,7(3):211-252
Occupational diseases Nos. 2108 and 2110 correspond to intervertebral disc-related diseases of the lumbar spine from many years of carrying or lifting heavy loads, occupations in extreme postures of full flexion or oscillation of the whole body when seated, and which compel the cessation of all activities which are or could be the cause for the origin, exacerbation or recurrence of the disease. These occupational diseases came into force at the start of 1993, but there have been considerable problems in their implementation. The present Part I of the contribution is the result of the work of an interdisciplinary study group and contains medical criteria for the assessment of possibly strain-related clinical characteristics and the evaluation of other possible causes. Part II is to be published in Volume 4/2005 and will deal with questions related to forced cessation and to the assessment of the loss of earning ability. Agreement was reached in many areas related to the assessment of occupational claims. This should allow for evidence-based decision making in the future for the occupational diseases Nos. 2108 and 2110. 相似文献
996.
997.
P. Nowakowski K. Ziaja T. Ludyga W. Kuczmik G. Biolik P. wik D. Ziaja 《Diseases of the esophagus》2007,20(4):358-360
Esophageus or gaster resection in patients with malignant disease is still a treatment of choice. It is obvious that each surgical procedure in these patients carries some possibility of complications. Esophageo-gastric or esophageo-jejuno anastomosis has a 4-27% frequency of fistula occurrence. All these result in 65% mortality in cases of poorer prognosis. The aim of this paper is not to present all types of complications but to objectively analyse the usefulness of the covered stent placement in the treatment of anastomotic fistulas. We present six patients who were treated for postoperative fistula of esophageo-gastric anastomosis (1 case) or esophageo-jejuno anastomosis (5 cases). All patients were treated with stapler suture for digestive tract reconstruction after malignancy removal during the primary surgical procedure. Signs and symptoms of suture leak between 5-8 days post-surgery were observed. Conservative therapy was not effective. Thus a new method of treatment was employed - covered stent placement. The procedure was performed under X-ray control. In all treated patients there was change for the better and quick reduction of secretion from the fistulas was observed. All patients were discharged from the department after several days and all had survived at 30 days follow-up. Covered esophageal stent placement seems to be a safe and promising method of treatment for patients with anastomotic fistula which significantly reduces mortality and improves quality of live. Our experiences confirms that of other investigators. 相似文献
998.
999.
The Broad Spectrum of Quality in Deceased Donor Kidneys 总被引:7,自引:6,他引:1
Jesse D. Schold Bruce Kaplan Rajendra S. Baliga Herwig-Ulf Meier-Kriesche 《American journal of transplantation》2005,5(4):757-765
The quality of the deceased donor organ clearly is one of the most crucial factors in determining graft survival and function in recipients of a kidney transplant. There has been considerable effort made towards evaluating these organs culminating in an amendment to allocation policy with the introduction of the expanded criteria donor (ECD) policy.
Our study, from first solitary adult deceased donor transplant recipients from 1996 to 2002 in the National Scientific Transplant Registry database, presents a donor kidney risk grade based on significant donor characteristics, donor–recipient matches and cold ischemia time, generated directly from their risk for graft loss. We investigated the impact of our donor risk grade in a naïve cohort on short- and long-term graft survival, as well as in subgroups of the population.
The projected half-lives for overall graft survival in recipients by donor risk grade were I (10.7 years), II (10.0 years), III (7.9 years), IV (5.7 years) and V (4.5 years). This study indicates that there is great variability in the quality of deceased donor kidneys and that the assessment of risk might be enhanced by this scoring system as compared to the simple two-tiered system of the current ECD classification. 相似文献
Our study, from first solitary adult deceased donor transplant recipients from 1996 to 2002 in the National Scientific Transplant Registry database, presents a donor kidney risk grade based on significant donor characteristics, donor–recipient matches and cold ischemia time, generated directly from their risk for graft loss. We investigated the impact of our donor risk grade in a naïve cohort on short- and long-term graft survival, as well as in subgroups of the population.
The projected half-lives for overall graft survival in recipients by donor risk grade were I (10.7 years), II (10.0 years), III (7.9 years), IV (5.7 years) and V (4.5 years). This study indicates that there is great variability in the quality of deceased donor kidneys and that the assessment of risk might be enhanced by this scoring system as compared to the simple two-tiered system of the current ECD classification. 相似文献
1000.
Five agents are currently approved for the treatment of chronic hepatitis B infection. This article will discuss the three agents for which the most extensive data are available; interferon (IFN), lamivudine, and adefovir, while the following article by Dr. Jules Dienstag will discuss the recently marketed agents, entecavir and peginterferon alfa-2a. The advantages of IFN are its finite duration of therapy (4–6 months), lack of emergence of resistance, and durability of response. On the negative side, response to IFN is less durable in patients with HBeAg-negative chronic hepatitis B virus (HBV). Also, use of IFN is limited by adverse effects and the mode of administration (daily to thrice-weekly subcutaneous injection). Lamivudine and adefovir are orally administered and have good tolerability and safety. Even in patients who experience a marked decrease in serum HBV DNA and loss of HBeAg, oral therapy needs to be continued for at least 6 months, to avoid the risk of reappearance of HBeAg and viremia. Rates of HBeAg seroconversion to anti-HBe-positivity increase with duration of lamivudine or adefovir therapy. The likelihood of development of resistance to lamivudine and associated viral breakthrough limits its long-term use. In patients with HBeAg-negative chronic hepatitis B, long-term therapy is usually required, as off-treatment relapse is common. The emergence of resistance to adefovir is delayed and infrequent, hence adefovir may be preferred in patients requiring long-term therapy. 相似文献